Cancer spread signals point to fructose and an experimental cell test

Last updated: October 21, 2026

Two studies address different pieces of the cancer-spread puzzle. Wistar Institute researchers found that fructose can act as a chemical signal released by ovarian cancer cells that survive chemotherapy, encouraging nearby cancer cells to spread. Separately, University of Illinois Chicago researchers developed a device that isolates scarce circulating pancreatic cancer cells from blood, potentially making it easier to study how those cells respond to drugs such as lidocaine.

Neither finding establishes a new cancer treatment. One describes a biological mechanism in a preclinical model; the other provides a research tool. The distinction is crucial because a plausible signal and a useful measurement method are steps toward better treatment, not proof that a diet change or medicine will improve outcomes for patients.

What researchers found in surviving cancer cells

The Wistar Institute study, published in Nature Aging, examined an aggressive form of ovarian cancer. Nearly all patients with ovarian cancer receive platinum-based chemotherapy, which often produces a strong initial response. Even so, the disease returns in most cases and typically spreads through the abdominal cavity. Metastasis accounts for roughly 90% of deaths from the disease.

The researchers focused on cancer cells that survive chemotherapy. Some of these cells are no longer dividing, but they remain biologically active and continue releasing molecules. The team separated the surviving cells from the substances they produced and exposed other cancer cells to those substances.

The released molecules alone were enough to significantly increase the ability of nearby cancer cells to spread. Further analysis identified fructose as one of the signals involved. In the preclinical model, high amounts of dietary fructose comparable to levels found in sugary drinks also encouraged spread, even without chemotherapy.

That last result suggests a possible connection between diet and cancer progression, but it does not show that dietary fructose causes ovarian cancer. Researchers have not tested whether reducing fructose intake improves patient outcomes. The study instead identifies a communication pathway that may help explain how cells remaining after therapy contribute to metastasis.

The mechanism also appeared to involve cell-to-cell attachment. The researchers found that fructose lowered cholesterol production inside neighboring cancer cells. Because cholesterol helps cells remain attached to one another, reduced production may make those cells less likely to stay together and more likely to spread under the conditions studied.

A faster way to study pancreatic cancer cells

The second study, published in Lab on a Chip, addresses a different obstacle: researchers struggle to collect enough circulating tumor cells for analysis. These are cancer cells that have left the original tumor and entered the bloodstream. Most never form new tumors, while some survive the journey and may contribute to distant spread.

Blood contains billions of normal cells and relatively few tumor cells, making isolation difficult. Researchers must recover the cancer cells without damaging them before exposing them to laboratory testing or potential drugs.

The University of Illinois Chicago team designed a small device with narrow channels that sorts cells according to physical characteristics such as size. In tests using blood from people with pancreatic cancer, the device recovered about eight times as many circulating tumor cells as the comparison method examined by the researchers. Some samples were processed in around 20 minutes.

Better recovery gives scientists more material to investigate cell behavior and possible responses to treatment candidates. Lidocaine, a medicine commonly used for numbing, is among the drugs researchers may examine using this approach. Earlier laboratory work suggested that it could influence cancer-cell behavior, including behavior associated with spread.

That does not mean lidocaine prevents pancreatic cancer metastasis in patients. Isolating tumor cells and testing a drug in a research setting is not equivalent to demonstrating clinical benefit. Human studies would still be needed to establish whether the medicine has a useful role, what an appropriate dose would be and whether its use is safe.

Why it matters

The immediate winner from the pancreatic cancer work is likely research capacity. A faster device that recovers more rare cells could support studies of blood-based tests, treatment selection and the behavior of cells that help tumors recur. Its value depends on whether the performance holds across different laboratories, samples and clinical workflows.

The fructose finding raises a different question: can a signal produced by treatment-surviving cells become a target for preventing spread? That possibility is scientifically important, but it also creates a risk of overinterpretation. Fructose is familiar from food and drink, which can make the result sound like evidence for a simple dietary intervention. The study does not support that conclusion.

For patients, the key dividing line is mechanism versus remedy. Fructose was identified as a signal within an experimental system. The cell-sorting device is a way to obtain better research material. Neither, by itself, demonstrates that a treatment improves survival or prevents recurrence.

Decision checklist for following cancer research claims

• Check whether the finding is preclinical, observational or clinical.** The fructose result was demonstrated in a preclinical model, not a dietary intervention trial in patients.
• Look for the actual endpoint.** A signal associated with spread is not the same as evidence that blocking it reduces metastasis or extends survival.
• Separate the research tool from the treatment.** Recovering more circulating pancreatic tumor cells can improve drug testing, but it does not show that lidocaine treats pancreatic cancer.
• Ask what has been tested in people.** Neither report establishes that changing fructose intake or taking lidocaine improves cancer outcomes.
• Discuss any proposed change with the oncology team.** Patients should not replace or modify cancer care based on a single research report.

What to watch next

For the ovarian cancer work, the crucial next questions include whether the fructose-mediated signal can be interrupted without disrupting normal metabolism and whether blocking it changes outcomes in more realistic models. Patient testing would also be needed before any dietary recommendation could be made.

For the pancreatic cancer device, researchers will need to determine whether its recovery advantage and processing speed remain useful beyond the samples examined. The next stage should connect better cell isolation to laboratory treatment studies and, eventually, carefully designed clinical research.

The broad lesson is straightforward: a mechanism, a measurement tool and an early treatment signal are not interchangeable with a proven therapy. Both studies could move research forward, but neither gives patients a reason to change treatment on their own.

Key takeaways

• Fructose was identified as one of the molecules used by chemotherapy-surviving ovarian cancer cells to encourage spread in a preclinical model.
• The result does not establish that dietary fructose causes ovarian cancer or that reducing it prevents recurrence.
• A cell-sorting device recovered about eight times as many circulating pancreatic cancer cells as the comparison method examined.
• Lidocaine remains an experimental research candidate for pancreatic cancer, not a proven treatment.
• Patients should not change cancer care without guidance from their oncology team.